SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series May archived by USPTO category 05/12

20120136148 - Photochromic compounds having at least two photochromic moieties: The present invention relates to photochromic compounds that include at least two photochromic moieties that are linked together by a multivalent linking group. The multivalent linking group can be selected so as to be flexible and/or substantially prevent electronic interaction between any two photochromic moieties through the multivalent linking group.... Agent: Transitions Optical, Inc.

20120136149 - Method for preparing 5-chloro-n-(methyl)thiophen-2-carboxamide derivative and intermediate used therein: Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)thiophene-2-carboxamide derivative, which is a inhibitor of blood coagulation factor Xa, in a high purity and yield; and a novel intermedicate used therein.... Agent: Green Cross Corporation

20120136150 - 4-(3-butynyl)aminopyrimidine derivatives as pest control agents for agricultural and horticultural use: Novel 4-(3-butynyl)aminopyrimidine derivatives represented by general formula [I] are useful as pest control agents. In general formula [I], R1 is a mono- or bi-cyclic ring which may contain 0 to 3 heteroatoms, for example, phenyl or oxazolyl; R2 is a hydrogen atom, —R, —OR, —C(O)OR, —C(O)NHR, —CONR2 (wherein R is... Agent: Sds Biotech K.k.

20120136151 - Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same: The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect... Agent:

20120136152 - Efficient synthetic method of 18f-mefway precursor: The present invention relates a novel method for preparing an 18F-mefway precursor. The present invention provides an efficient synthetic method of an 18F-mefway precursor, which comprises an improved the acid chloride coupling reaction and proper reduction condition to suppress breakdown of amide bond and can obtain the precursor in high... Agent: Industry-academic Cooperation Foundation, Yonsei University

20120130068 - 5,6-dihydro-1h-pyridin-2-one compounds: P

20120130069 - Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms,... Agent:

20120130070 - Compounds having npy y5 receptor antagonistic activity: s

20120130071 - Method for oxidizing methane: Platinum(II) complexes and the use of these complexes for oxidation of methane to methyl sulfate are disclosed, the catalyst having, as ligands, a network based on aromatic N-heterocycles which has at least 2 coordinative nitrogen atoms per platinum atom, and the complex anion is selected from a halide, hydrogensulfate, hydrogensulfite,... Agent: Studiengesellschaft Kohle Mbh

20120130072 - Process for the preparation of dihydroquinazolines: The present invention relates to a process for the preparation of dihydroquinazolines, which are used for the production of medicaments.... Agent: Aicuris Gmbh & Co. Kg

20120130073 - Inhibitors of syk and jak protein kinases: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such... Agent: Portola Pharmaceuticals, Inc.

20120123114 - Quinazoline derivatives having tyrosine kinase inhibitory activity: P

20120123115 - Cyclic guanidine ionic liquid: wherein R1 and R2 each is independently an alkyl group or an alkoxyalkyl group, X is a methylene group, an oxygen atom, a sulfur atom, or R3N; R3 is an alkyl group, an alkoxyalkyl group, or an acyl group; l, m, and n each is an integer in the range... Agent: Nippon Steel Chemical Co., Ltd.

20120123116 - Application of 2, 3 - dihydro-3 - hydroxymethyl -6 - amino - [1,4 ] - benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells: An application of 2,3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in the preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells, wherein the concentration of the 2,3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in the preparation of drugs effectively inducing mouse embryonic stem cells to differentiate to vascular endothelial cells is 1˜20 μM. The 2,3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine provided by the... Agent: Shandong University

20120123117 - Organometallic complex, and light-emitting element, light-emitting device, and electronic device including the organometallic complex: An organometallic complex is provided by which favorable red-color light emission can be obtained. Further, an organometallic complex having a peak of light emission at about 620 nm is provided because the wavelength of light which is perceived as excellent red-color light is about 620 nm. Furthermore, an organometallic complex... Agent: Semiconductor Energy Laboratory Co., Ltd.

20120123118 - process for the preparation of nitroorotic acid: Subject of the present invention is a new improved process for the preparation of nitroorotic acid via nitration of orotic acid.... Agent: Boehringer Ingelheim International Gmbh & Co. Kg

20120123119 - Acyclic nucleoside derivatives: b

20120123120 - No-carrier-added nucleophilic [f-18] fluorination of aromatic compounds: Phenyliodonium ylide derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are shown for use as precursors in aromatic nucleophilic substitution reactions. The iodonium ylide group is substituted by nucleophiles such as halide ions to provide the corresponding haloaryl derivatives. No-carrier-added [F-18]fluoride ion exclusively... Agent: The Regents Of The University Of California

20120116077 - [1,2,4]thiadiazin-3-yl acetic acid compound[[s]] and methods of making the acetic acid compound: The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Anadys Pharmaceuticals, Inc.

20120116078 - Phosphorus-containing bisphenols and preparing method thereof: The Phosphorus-containing bisphenols and preparing method thereof are disclosed. A method for producing the phosphorus-containing bisphenol of the formula (1) includes reacting compounds respectively defined by a formula (a), (b), (c) and an acid catalyst to yield compounds of phosphorus-containing bisphenol.... Agent: National Chunghsing University

20120116079 - Phosphonate fluorescent dyes and conjugates: Reagents are provided for the introduction of phosphonate groups into fluorescent dyes. Methods are also provided for preparing dye conjugates.... Agent:

20120116080 - Process for the stereoselective preparation of bicyclic heterocycles: and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia... Agent: Boehringer Ingelheim International Gmbh

20120116081 - Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine: d

20120116082 - Process for the preparation of rosuvastatin salts: The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in... Agent:

20120116083 - Heteroaromatic pyrazinoylguanidine sodium channel blockers: e

20120108808 - Method for preparing (s)-5-chloro-n-((3-(4-(5,6-dihydro-4h-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives: Provided is a method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors, and said method using 1-fluoro-4-nitrobenzen as a starting material. According to the method of the present invention, (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa... Agent: Legochem Bioscience Ltd.

20120108809 - Process for preparation of efavirenz: An improved process for Efavirenz, which has several advantages over reported methods like low cost, high yield, better optical purity and industrial feasibility.... Agent: Lupin Limited

20120108810 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.... Agent: Rigel Pharmaceuticals, Inc.

20120108811 - Process for preparing temozolomide: This present invention provides an improved process for preparing Temozolomide (TMZ) stable at room temperature for at least 18 months. This present invention also relates to Temozolomide stable at room temperature for at least 18 months.... Agent: Formosa Laboratories Inc.

20120108812 - Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines: Processes including preparation of trans-4-[(3-amino-5-oxo-4,5-dihydro-[1,2,4]triazin-6-ylmethyl)-carbamoyl]-cyclohexanecarboxylic acid methyl ester, and its conversion to trans-4-(4-amino-5-substituted-imidazo[5,1-f][1,2,4]triazin-7-yl)-cyclohexanecarboxylic acid compounds.... Agent: Osi Pharmaceuticals ,inc.

20120108813 - Fused pyrimidineone compounds as trpv3 modulators: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating... Agent: Glenmark Pharmaceuticals S.a.

20120108814 - Process 738: Processes for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline, salts thereof, and the intermediates used in the process are described.... Agent: Astrazeneca Ab

20120108815 - Bifunctional/polyfunctional dopamine d2/d3 agonist as neuroprotective agents for treatment of neurodegenerative diseases: A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided.... Agent: Wayne State University

20120108816 - Process for preparing 1,4-bishydroxyethylpiperazine: p

20120108817 - Acetyl pyrrolidinyl indole derivative: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen... Agent: Msd K.k.